ARCHIVES

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

Kennedy Bills Would Authorize Senior Scientist Service, New Foundation, Construction Grants

July 28, 1989

FDA Lists Therapies being Tested For AIDS, Opportunistic Infections

January 24, 1992

FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer

September 24, 1999

Clinical Societies, Patient Groups Need New Alliance, Glick Proposes to ASCO

May 24, 1996

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

September 29, 2006

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

March 30, 2012